Cemiplimab and Cetuximab Before Surgery for Recurrent Oral Cavity and HPV-Negative Oropharyngeal Cancer
This study is looking at whether giving two medicines, cemiplimab and cetuximab, before surgery can help control oral cavity squamous cell carcinoma or HPV-negative oropharyngeal squamous cell carcinoma that has come back. You might be able to join if you are at least 18 years old, have this type of cancer that can be removed by surgery, and it has returned at least 3 months after your previous treatment. The main goal is to see how well the combination of cemiplimab and cetuximab works to shrink the tumor (overall response rate). Researchers will also look at safety and other ways to measure how well the treatment works. The study is currently unclear about its recruitment status.
- Study design
- This is an interventional study planning to enroll 17 participants. It is not specified if it is randomized or blinded.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed for safety and adverse events (side effects) through study completion, which is an average of 1 year.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Cemiplimab and Cetuximab Prior Salvage Surgery in Patients With Recurrent Oral Cavity and HPV-negative Oropharyngeal Squamous Cell Carcinoma
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Luana Guimaraes De Sousa, MD · PRINCIPAL_INVESTIGATOR · M.D. Anderson Cancer Center
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Safety and adverse events (AEs)Through study completion; an average of 1 year
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0